Susquehanna International Group, LLP Exelixis, Inc. Put Options Transaction History

Susquehanna International Group, LLP

$527 Billion
Q2 2024

Put Options

28 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 15, 2024	BUY	$20.34 - $23.73 $1.76 Million - $2.05 Million	86,500 Added 37.49%	317,200 $7.13 Million
Q1 2024 May 07, 2024	SELL	$20.17 - $23.93 $556,692 - $660,468	-27,600 Reduced 10.69%	230,700 $5.47 Million
Q4 2023 Feb 14, 2024	BUY	$19.25 - $24.13 $2.33 Million - $2.92 Million	121,000 Added 88.13%	258,300 $6.2 Million
Q3 2023 Nov 14, 2023	BUY	$19.04 - $22.74 $1.72 Million - $2.06 Million	90,500 Added 193.38%	137,300 $3 Million
Q2 2023 Aug 11, 2023	SELL	$18.17 - $20.48 $2.92 Million - $3.29 Million	-160,800 Reduced 77.46%	46,800 $894,000
Q1 2023 May 16, 2023	SELL	$16.3 - $19.41 $665,040 - $791,928	-40,800 Reduced 16.43%	207,600 $4.03 Million
Q4 2022 Feb 14, 2023	SELL	$14.96 - $17.39 $200,464 - $233,026	-13,400 Reduced 5.12%	248,400 $3.98 Million
Q3 2022 Nov 14, 2022	BUY	$15.68 - $22.27 $942,368 - $1.34 Million	60,100 Added 29.8%	261,800 $4.11 Million
Q2 2022 Aug 15, 2022	BUY	$17.44 - $23.16 $742,944 - $986,616	42,600 Added 26.78%	201,700 $4.2 Million
Q1 2022 May 16, 2022	SELL	$17.03 - $22.67 $2.45 Million - $3.26 Million	-143,700 Reduced 47.46%	159,100 $3.61 Million
Q4 2021 Feb 14, 2022	BUY	$15.84 - $21.88 $535,392 - $739,544	33,800 Added 12.57%	302,800 $5.54 Million
Q3 2021 Nov 15, 2021	SELL	$16.3 - $21.14 $1.94 Million - $2.51 Million	-118,900 Reduced 30.65%	269,000 $5.69 Million
Q2 2021 Aug 11, 2021	BUY	$17.95 - $25.56 $576,195 - $820,476	32,100 Added 9.02%	387,900 $7.07 Million
Q1 2021 May 17, 2021	SELL	$20.53 - $25.22 $3.79 Million - $4.66 Million	-184,800 Reduced 34.18%	355,800 $8.04 Million
Q4 2020 Feb 16, 2021	BUY	$18.39 - $24.8 $1.78 Million - $2.41 Million	97,000 Added 21.87%	540,600 $10.9 Million
Q3 2020 Nov 16, 2020	BUY	$20.67 - $26.94 $847,470 - $1.1 Million	41,000 Added 10.18%	443,600 $10.8 Million
Q2 2020 Aug 14, 2020	SELL	$16.46 - $27.42 $692,966 - $1.15 Million	-42,100 Reduced 9.47%	402,600 $9.56 Million
Q1 2020 May 15, 2020	SELL	$14.46 - $21.8 $2.08 Million - $3.14 Million	-144,000 Reduced 24.46%	444,700 $7.66 Million
Q4 2019 Feb 14, 2020	SELL	$15.15 - $18.89 $1.51 Million - $1.88 Million	-99,500 Reduced 14.46%	588,700 $10.4 Million
Q3 2019 Nov 14, 2019	SELL	$17.68 - $22.65 $1.85 Million - $2.37 Million	-104,700 Reduced 13.2%	688,200 $12.2 Million
Q2 2019 Aug 14, 2019	BUY	$18.93 - $24.75 $338,847 - $443,025	17,900 Added 2.31%	792,900 $16.9 Million
Q1 2019 May 15, 2019	BUY	$19.6 - $24.76 $444,920 - $562,052	22,700 Added 3.02%	775,000 $18.4 Million
Q4 2018 Feb 14, 2019	SELL	$13.65 - $21.8 $3.4 Million - $5.43 Million	-248,900 Reduced 24.86%	752,300 $14.8 Million
Q3 2018 Nov 14, 2018	BUY	$15.87 - $22.4 $5.08 Million - $7.17 Million	320,200 Added 47.02%	1,001,200 $17.7 Million
Q2 2018 Aug 14, 2018	SELL	$18.56 - $22.45 $1.16 Million - $1.41 Million	-62,700 Reduced 8.43%	681,000 $14.7 Million
Q1 2018 May 15, 2018	SELL	$22.15 - $31.89 $13 Million - $18.6 Million	-584,700 Reduced 44.02%	743,700 $16.5 Million
Q4 2017 Feb 14, 2018	BUY	$24.23 - $30.93 $6.61 Million - $8.44 Million	272,900 Added 25.86%	1,328,400 $40.4 Million
Q3 2017 Nov 14, 2017	BUY	$23.35 - $29.24 $24.6 Million - $30.9 Million	1,055,500	1,055,500 $25.6 Million

Others Institutions Holding EXEL

# of Institutions

460

Shares Held

240M

Call Options Held

2.04M

Put Options Held

1.29M

Black Rock Inc. New York, NY

33.5M
Shares

$881 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

29.7M
Shares

$780 Million
0.01% of portfolio
Farallon Capital Management LLC San Francisco, CA

27.1M
Shares

$713 Million
2.95% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

15.2M
Shares

$399 Million
0.6% of portfolio
State Street Corp Boston, MA

12.6M
Shares

$331 Million
0.01% of portfolio

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $8.46B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account